Health
Pfizer’s Coronavirus Vaccine Candidate Shows Promise in Early Trial – Myhealthyclick
A coronavirus vaccine candidate developed by Pfizer has shown promising results in Phase I/II clinical trials. The experimental vaccine based on a genetic code called messenger RNA has been found effective at sparking a strong immune response, preventing COVI…
Pfizers experimental coronavirus vaccine, which is based on
RNA gene technology, has shown promising results in an early trial.
According to a news release from the journal Nature, the vaccine
candidate, called BNT162b1, elicited a robust immune response in participants,
which increased with dose level and with a second dose.
Dr. Judith Absalon of Pfizer, who led the early clinical
phase I/II trial, said BNT162b1 is based on messenger RNA, a genetic code that
helps kick-start the immune r…
-
Noosa News14 hours agoSuncorp Stadium upgrades to rival Sydney as seat capacity and infrastructure prioritised
-
Business16 hours agoDroneShield announces new $13 million counter-drone facility as employees top 400
-
General22 hours agoHopes for peace but pain lingers on Oct 7 anniversary
-
General12 hours agoRescuers pull children from the rubble of Indonesian boarding school collapse